ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus

American Journal of Gastroenterology

Volumn 111, Issue 1, 2016, Pages 30-50

  Shaheen, Nicholas J ^a   Falk, Gary W ^b   Iyer, Prasad G ^c   Gerson, Lauren B ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; DECISION TREE; HUMAN; PRACTICE GUIDELINE; RISK FACTOR;

BARRETT ESOPHAGUS; DECISION TREES; HUMANS; RISK FACTORS;

EID: 84955391043     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.322     Document Type: Article

References (198)

1. Boeckxstaens G, El-Serag HB, Smout AJ et al. Symptomatic refl ux disease: The present, the past and the future. Gut 2014; 63: 1185-93.
2. El-Serag HB, Sweet S, Winchester CC et al. Update on the epidemiology of gastro-oesophageal refl ux disease: a systematic review. Gut 2014; 63: 871-80.
3. Singh S, Sharma AN, Murad MH et al. Central adiposity is associated with increased risk of esophageal infl ammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 1399-412.
4. Rubenstein JH, Mattek N, Eisen G. Age-and sex-specifi c yield of Barrett's esophagus by endoscopy indication. Gastrointest Endosc 2010; 71: 21-7.
5. Rubenstein JH, Morgenstern H, Appelman H et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013; 108: 353-62.
6. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-53.
7. Hur C, Miller M, Kong CY et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013; 119: 1149-58.
8. Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336: 924-6.
9. Jung KW, Talley NJ, Romero Y et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol 2011; 106: 1447-55.
10. Fitzgerald RC, Di Pietro M, Ragunath K et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2014; 63: 7-42.
11. Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103: 1049-57.
12. Kelty CJ, Gough MD, Van Wyk Q et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007; 42: 1271-4.
13. Liu W, Hahn H, Odze RD et al. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am J Gastroenterol 2009; 104: 816-24.
14. Bandla S, Peters JH, Ruff D et al. Comparison of cancer-associated genetic abnormalities in columnar-lined esophagus tissues with and without goblet cells. Ann Surg 2014; 260: 72-80.
15. Harrison R, Perry I, Haddadin W et al. Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007; 102: 1154-61.
16. Shaheen NJ, Green B, Medapalli RK et al. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Gastroenterology 2005; 129: 429-36.
17. Crockett SD, Lippmann QK, Dellon ES et al. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Clin Gastroenterol Hepatol 2009; 7: 613-23.
18. Byrne JP, Bhatnagar S, Hamid B et al. Comparative study of intestinal metaplasia and mucin staining at the cardia and esophagogastric junction in 225 symptomatic patients presenting for diagnostic open-access gastroscopy. Am J Gastroenterol 1999; 94: 98-103.
19. Weston AP, Krmpotich PT, Cherian R et al. Prospective evaluation of intestinal metaplasia and dysplasia within the cardia of patients with Barrett's esophagus. Dig Dis Sci 1997; 42: 597-602.
20. Zaninotto G, Avellini C, Barbazza R et al. Prevalence of intestinal metaplasia in the distal oesophagus, oesophagogastric junction and gastric cardia in symptomatic patients in north-east Italy: a prospective, descriptive survey. The Italian Ulcer Study Group "GISU". Dig Liver Dis 2001; 33: 316-21.
21. Ogiya K, Kawano T, Ito E et al. Lower esophageal palisade vessels and the defi nition of Barrett's esophagus. Dis Esophagus 2008; 21: 645-9.
22. Amano Y, Ishimura N, Furuta K et al. Which landmark results in a more consistent diagnosis of Barrett's esophagus, the gastric folds or the palisade vessels? Gastrointest Endosc 2006; 64: 206-11.
23. Sharma P, Morales TG, Sampliner RE. Short segment Barrett's esophagus-the need for standardization of the defi nition and of endoscopic criteria. Am J Gastroenterol 1998; 93: 1033-6.
24. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: The Prague C & M criteria. Gastroenterology 2006; 131: 1392-9.
25. Khandwalla HE, Graham DY, Kramer JR et al. Barrett's Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what's next. Am J Gastroenterol 2014; 109: 178-82.
26. Johansson J, Hakansson HO, Mellblom L et al. Prevalence of precancerous and other metaplasia in the distal oesophagus and gastro-oesophageal junction. Scand J Gastroenterol 2005; 40: 893-902.
27. Ronkainen J, Aro P, Storskrubb T et al. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-31.
28. Zagari RM, Fuccio L, Wallander MA et al. Gastro-oesophageal refl ux symptoms, oesophagitis and Barrett's oesophagus in the general population: The Loiano-Monghidoro study. Gut 2008; 57: 1354-9.
29. Lagergren J, Bergstrom R, Lindgren A et al. Symptomatic gastroesophageal refl ux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
30. Lieberman DA. Risk factors for Barrett's esophagus in community-based practice. Am J Gastroenterol 1997; 92: 1293-7.
31. Taylor JB, Rubenstein JH. Meta-analyses of the eff ect of symptoms of gastroesophageal refl ux on the risk of Barrett's esophagus. Am J Gastroenterol 2010; 105: 1729-37.
32. Th rift AP, Kramer JR, Qureshi Z et al. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. The Am J Gastroenterol 2013; 108: 915-22.
33. Cook MB, Wild CP, Forman D. A systematic review and meta-analysis of the sex ratio for Barrett's esophagus, erosive refl ux disease, and nonerosive refl ux disease. Am J Epidemiol 2005; 162: 1050-61.
34. Rubenstein JH, Scheiman JM, Sadeghi S et al. Esophageal adenocarcinoma incidence in individuals with gastroesophageal refl ux: synthesis and estimates from population studies. Am J Gastroenterol 2011; 106: 254-60.
35. Andrici J, Cox MR, Eslick GD. Cigarette smoking and the risk of Barrett's esophagus: a systematic review and meta-analysis. J Gastroenterol Hepatol 2013; 28: 1258-73.
36. Anderson LA, Cantwell MM, Watson RGP et al. The association between alcohol and refl ux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma. Gastroenterology 2009; 136: 799-805.
37. Kubo A, Levin TR, Block G et al. Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology 2009; 136: 806-15.
38. Th rift AP, Kramer JR, Richardson PA et al. No signifi cant eff ects of smoking or alcohol consumption on risk of Barrett's esophagus. Dig Dis Sci 2014; 59: 108-16.
39. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal refl ux disease and its complications. Ann Intern Med 2005; 143: 199-211.
40. Th rift AP, Kramer JR, Alsarraj A et al. Fat mass by bioelectrical impedance analysis is not associated with increased risk of Barrett esophagus. J Clin Gastroenterol 2014; 48: 218-23.
41. Kubo A, Cook MB, Shaheen NJ et al. Sex-specifi c associations between body mass index, waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 2013; 62: 1684-91.
42. Chak A, Lee T, Kinnard MF et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults. Gut 2002; 51: 323-8.
43. Chak A, Faulx A, Kinnard M et al. Identifi cation of Barrett's esophagus in relatives by endoscopic screening. Am J Gastroenterol 2004; 99: 2107-14.
44. Orloff M, Peterson C, He X et al. Germline mutations in MSR1, ASCC1, and CTHRC1 in patients with Barrett esophagus and esophageal adenocarcinoma. JAMA 2011; 306: 410-9.
45. Ek WE, Levine DM, D'Amato M et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal refl ux. J Natl Cancer Inst 2013; 105: 1711-8.
46. Su Z, Gay LJ, Strange A et al. Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus. Nat Genet 2012; 44: 1131-6.
47. Levine DM, Ek WE, Zhang R et al. A genome-wide association study identifi es new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013; 45: 1487-93.
48. Corley DA, Kubo A, Levin TR et al. Race, ethnicity, sex and temporal diff erences in Barrett's oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009; 58: 182-8.
49. Abrams JA, Fields S, Lightdale CJ et al. Racial and ethnic disparities in the prevalence of Barrett's esophagus among patients who undergo upper endoscopy. Clin Gastroenterol Hepatol 2008; 6: 30-4.
50. Keyashian K, Hua V, Narsinh K et al. Barrett's esophagus in Latinos undergoing endoscopy for gastroesophageal refl ux disease symptoms. Dis Esophagus 2013; 26: 44-9.
51. Leggett CL, Nelsen EM, Tian J et al. Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin Proc 2013; 88: 157-65.
52. Iyer PG, Borah BJ, Heien HC et al. Association of Barrett's esophagus with type II diabetes mellitus: results from a large population-based casecontrol study. Clin Gastroenterol Hepatol 2013; 11: 1108-14.
53. Leggett CL, Gorospe EC, Calvin AD et al. Obstructive sleep apnea is a risk factor for Barrett's esophagus. Clin Gastroenterol Hepatol 2014; 12: 583-8.
54. Rubenstein JH, Inadomi JM, Scheiman J et al. Association between Helico bacter pylori and Barrett's esophagus, erosive esophagitis, and gastro esophageal refl ux symptoms. Clin Gastroenterol Hepatol 2014; 12: 239-45.
55. Fischbach LA, Graham DY, Kramer JR et al. Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol 2014; 109: 357-68.
56. Gopal DV, Lieberman DA, Magaret N et al. Risk factors for dysplasia in patients with Barrett's esophagus (BE): results from a multicenter consortium. Dig Dis Sci 2003; 48: 1537-41.
57. Singh S, Garg SK, Singh PP et al. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Gut 2014; 63: 1229-37.
58. Zhang S, Zhang XQ, Ding XW et al. Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer 2014; 110: 2378-88.
59. Singh S, Singh AG, Singh PP et al. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2013; 11: 620-9.
60. Desai TK, Krishnan K, Samala N et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012; 61: 970-6.
61. Singh S, Manickam P, Amin AV et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis. Gastrointest Endosc 2014; 79: 897-909.
62. Rastogi A, Puli S, El-Serag HB et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc 2008; 67: 394-8.
63. Shaheen NJ, Sharma P, Overholt BF et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009; 360: 2277-88.
64. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfi mer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62: 488-98.
65. Sikkema M, de Jonge PJ, Steyerberg EW et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010; 8: 235-44.
66. Spechler SJ. Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA 2013; 310: 627-36.
67. Dulai GS, Guha S, Kahn KL et al. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002; 122: 26-33.
68. Hvid-Jensen F, Pedersen L, Drewes AM et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365: 1375-83.
69. Barbiere JM, Lyratzopoulos G. Cost-eff ectiveness of endoscopic screening followed by surveillance for Barrett's esophagus: a review. Gastroenterology 2009; 137: 1869-76.
70. Gerson LB, Groeneveld PW, Triadafi lopoulos G. Cost-eff ectiveness model of endoscopic screening and surveillance in patients with gastroesophageal refl ux disease. Clin Gastroenterol Hepatol 2004; 2: 868-79.
71. Inadomi JM, Sampliner R, Lagergren J et al. Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis. Ann Intern Med 2003; 138: 176-86.
72. Rubenstein JH, Inadomi JM, Brill JV et al. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy vs. conventional upper endoscopy. Clin Gastroenterol Hepatol 2007; 5: 312-8.
73. Gerson L, Lin OS. Cost-benefi t analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus. Clin Gastroenterol Hepatol 2007; 5: 319-25.
74. Nietert PJ, Silverstein MD, Mokhashi MS et al. Cost-eff ectiveness of screening a population with chronic gastroesophageal refl ux. Gastrointest Endosc 2003; 57: 311-8.
75. Sami SS, Dunagan KT, Johnson ML et al. A randomized comparative eff ectiveness trial of novel endoscopic techniques and approaches for Barrett's esophagus screening in the community. Am J Gastroenterol 2015; 110: 148-58.
76. Kadri SR, Lao-Sirieix P, O'Donovan M et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010; 341: c4372.
77. Chang JY, Talley NJ, Locke GR 3rd et al. Population screening for barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc 2011; 86: 1174-80.
78. Eloubeidi MA, Provenzale D. Does this patient have Barrett's esophagus? The utility of predicting Barrett's esophagus at the index endoscopy. Am J Gastroenterol 1999; 94: 937-43.
79. Ganz RA, Allen JI, Leon S et al. Barrett's esophagus is frequently overdiagnosed in clinical practice: results of the Barrett's Esophagus Endoscopic Revision (BEER) study. Gastrointest Endosc 2014; 79: 565-73.
80. Rodriguez S, Mattek N, Lieberman D et al. Barrett's esophagus on repeat endoscopy: should we look more than once? Am J Gastroenterol 2008; 103: 1892-7.
81. Hanna S, Rastogi A, Weston AP et al. Detection of Barrett's esophagus after endoscopic healing of erosive esophagitis. Am J Gastroenterol 2006; 101: 1416-20.
82. Modiano N, Gerson LB. Risk factors for the detection of Barrett's esophagus in patients with erosive esophagitis. Gastrointest Endosc 2009; 69: 1014-20.
83. Rex DK, Cummings OW, Shaw M et al. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 2003; 125: 1670-7.
84. Farrow DC, Vaughan TL, Sweeney C et al. Gastroesophageal refl ux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 2000; 11: 231-8.
85. Ward EM, Wolfsen HC, Achem SR et al. Barrett's esophagus is common in older men and women undergoing screening colonoscopy regardless of refl ux symptoms. Am J Gastroenterol 2006; 101: 12-17.
86. Gerson LB, Shetler K, Triadafi lopoulos G. Prevalence of Barrett's esophagus in asymptomatic individuals. Gastroenterology 2002; 123: 461-7.
87. Yousef F, Cardwell C, Cantwell MM et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: A systematic review and meta-analysis. Am J Epidemiol 2008; 168: 237-49.
88. Th rift AP, Kendall BJ, Pandeya N et al. A clinical risk prediction model for Barrett esophagus. Cancer Prev Res 2012; 5: 1115-23.
89. Th rift AP, Garcia JM, El-Serag HB. A multibiomarker risk score helps predict risk for Barrett's esophagus. Clin Gastroenterol Hepatol 2014; 12: 1267-71.
90. Shariff MK, Bird-Lieberman EL, O'Donovan M et al. Randomized crossover study comparing effi cacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointest Endosc 2012; 75: 954-61.
91. Peery AF, Hoppo T, Garman KS et al. Feasibility, safety, acceptability, and yield of offi ce-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc 2012; 75: 945-53.
92. Alashkar B, Faulx AL, Hepner A et al. Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus. Clin Gastroenterol Hepatol 2014; 12: 785-92.
93. Bhardwaj A, Hollenbeak CS, Pooran N et al. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett's esophagus in patients with gastroesophageal refl ux disease. Am J Gastroenterol 2009; 104: 1533-9.
94. Benaglia T, Sharples LD, Fitzgerald RC et al. Health benefi ts and cost eff ectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013; 144: 62-73.
95. Rice TW, Blackstone EH, Goldblum JR et al. Superfi cial adenocarcinoma of the esophagus. J Th orac Cardiovasc Surg 2001; 122: 1077-90.
96. Incarbone R, Bonavina L, Saino G et al. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Surg Endosc 2002; 16: 263-6.
97. Ferguson MK, Durkin A. Long-term survival after esophagectomy for Barrett's adenocarcinoma in endoscopically surveyed and nonsurveyed patients. J Gastrointest Surg 2002; 6: 29-35.
98. van Sandick JW, van Lanschot JJ, Kuiken BW et al. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 1998; 43: 216-22.
99. Peters JH, Clark GW, Ireland AP et al. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. J Th orac Cardiovasc Surg 1994; 108: 813-21.
100. Verbeek RE, Leenders M, Ten Kate FJ et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a populationbased cohort study. Am J Gastroenterol 2014; 109: 1215-22.
101. Bhat SK, McManus DT, Coleman HG et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 2015; 64: 20-25.
102. Corley DA, Mehtani K, Quesenberry C et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013; 145: 312-9.
103. Abrams JA, Kapel RC, Lindberg GM et al. Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol 2009; 7: 736-42.
104. Kruijshaar ME, Siersema PD, Janssens AC et al. Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc 2007; 65: 26-30.
105. Sami SS, Subramanian V, Butt WM et al. High defi nition vs. standard defi nition white light endoscopy for detecting dysplasia in patients with Barrett's esophagus. Dis Esoph 2014; doi:10. 1111/dote 12288; e-pub ahead of print.
106. Gupta N, Gaddam S, Wani SB et al. Longer inspection time is associated with increased detection of high-grade dysplasia and esophageal adenocarcinoma in Barrett's esophagus. Gastrointest Endosc 2012; 76: 531-8.
107. Enestvedt BK, Lugo R, Guarner-Argente C et al. Location, location, location: does early cancer in Barrett's esophagus have a preference? Gastrointest Endosc 2013; 78: 462-7.
108. Kariyawasam VC, Bourke MJ, Hourigan LF et al. Circumferential location predicts the risk of high-grade dysplasia and early adenocarcinoma in short-segment Barrett's esophagus. Gastrointest Endosc 2012; 75: 938-44.
109. Montgomery E, Bronner MP, Goldblum JR et al. Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffi rmation. Hum Pathol 2001; 32: 368-78.
110. Fitzgerald RC, Saeed IT, Khoo D et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001; 46: 1892-8.
111. Abela JE, Going JJ, Mackenzie JF et al. Systematic four-quadrant biopsy detects Barrett's dysplasia in more patients than nonsystematic biopsy. Am J Gastroenterol 2008; 103: 850-5.
112. Reid BJ, Blount PL, Feng Z et al. Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol 2000; 95: 3089-96.
113. Peters FP, Brakenhoff KP, Curvers WL et al. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endosc 2008; 67: 604-9.
114. Mino-Kenudson M, Hull MJ, Brown I et al. EMR for Barrett's esophagusrelated superfi cial neoplasms off ers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc 2007; 66: 660-6.
115. Levine DS, Blount PL, Rudolph RE et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus. Am J Gastroenterol 2000; 95: 1152-7.
116. Kumaravel A, Lopez R, Brainard J et al. Brush cytology vs. endoscopic biopsy for the surveillance of Barrett's esophagus. Endoscopy 2010; 42: 800-5.
117. Anandasabapathy S, Sontag S, Graham DY et al. Computer-assisted brush-biopsy analysis for the detection of dysplasia in a high-risk Barrett's esophagus surveillance population. Dig Dis Sci 2011; 56: 761-6.
118. Johanson JF, Frakes J, Eisen D. Computer-assisted analysis of abrasive transepithelial brush biopsies increases the eff ectiveness of esophageal screening: a multicenter prospective clinical trial by the endocdx collaborative group. Dig Dis Sci 2011; 56: 767-72.
119. Sharma P, Hawes RH, Bansal A et al. Standard endoscopy with random biopsies vs. narrow band imaging targeted biopsies in Barrett's oeso phagus: a prospective, international, randomised controlled trial. Gut 2013; 62: 15-21.
120. Qumseya BJ, Wang H, Badie N et al. Advanced imaging technologies increase detection of dysplasia and neoplasia in patients with Barrett's esophagus: a meta-analysis and systematic review. Clin Gastroenterol Hepatol 2013; 11: 1562-70.
121. Kerkhof M, van Dekken H, Steyerberg EW et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007; 50: 920-7.
122. Curvers WL, ten Kate FJ, Krishnadath KK et al. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-30.
123. Duits LC, Phoa KN, Curvers WL et al. Barrett's oesophagus patients with low-grade dysplasia can be accurately risk-stratifi ed after histological review by an expert pathology panel. Gut 2015; 64: 700-6.
124. Alikhan M, Rex D, Khan A et al. Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc 1999; 50: 23-6.
125. Montgomery E, Goldblum JR, Greenson JK et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001; 32: 379-88.
126. Horvath B, Singh P, Xie H et al. Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefi nite for dysplasia. J Gastroenterol Hepatol 2014; 30: 262-7.
127. Younes M, Lauwers GY, Ertan A et al. The signifi cance of "indefi nite for dysplasia" grading in Barrett metaplasia. Arch Pathol Lab Med 2011; 135: 430-2.
128. Fels Elliott DR, Fitzgerald RC. Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol 2013; 29: 437-45.
129. Merlo LM, Shah NA, Li X et al. A comprehensive survey of clonal diversity measures in Barrett's esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 2010; 3: 1388-97.
130. Reid BJ, Sanchez CA, Blount PL et al. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology 1993; 105: 119-29.
131. Rabinovitch PS, Longton G, Blount PL et al. Predictors of progression in Barrett's esophagus III: baseline fl ow cytometric variables. Am J Gastroenterol 2001; 96: 3071-83.
132. Maley CC, Galipeau PC, Finley JC et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006; 38: 468-73.
133. Weaver JM, Ross-Innes CS, Shannon N et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet 2014; 46: 837-43.
134. Kastelein F, Biermann K, Steyerberg EW et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2013; 62: 1676-83.
135. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-97.
136. Bhat S, Coleman HG, Yousef F et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. [Erratum appears in J Natl Cancer Inst 2013;105:581]. J Natl Cancer Inst 2011; 103: 1049-57.
137. Kastelein F, Spaander MC, Steyerberg EW et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2013; 11: 382-8.
138. Hillman LC, Chiragakis L, Shadbolt B et al. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004; 180: 387-91.
139. Nguyen DM, El-Serag HB, Henderson L et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009; 7: 1299-304.
140. Gammon MD, Terry MB, Arber N et al. Nonsteroidal anti-infl ammatory drug use associated with reduced incidence of adenocarcinomas of the eso phagus and gastric cardia that overexpress cyclin D1: a populationbased study. Cancer Epidemiol Biomarkers Prev 2004; 13: 34-9.
141. Corley DA, Kerlikowske K, Verma R et al. Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and metaanalysis. Gastroenterology 2003; 124: 47-56.
142. Phoa KN, van Vilsteren FG, Weusten BL et al. Radiofrequency ablation vs. endoscopic surveillance for patients with Barrett esophagus and lowgrade dysplasia: a randomized clinical trial. JAMA 2014; 311: 1209-17.
143. Jankowski J, Barr H. Improving surveillance for Barrett's oesophagus: AspECT and BOSS trials provide an evidence base. BMJ 2006; 332: 1512.
144. Jayasekera C, Taylor AC, Desmond PV et al. Added value of narrow band imaging and confocal laser endomicroscopy in detecting Barrett's esophagus neoplasia. Endoscopy 2012; 44: 1089-95.
145. Pech O, Behrens A, May A et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with highgrade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut 2008; 57: 1200-6.
146. Manner H, Pech O, Heldmann Y et al. Effi cacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion. Clin Gastroenterol Hepatol 2013; 11: 630-5.
147. Prasad GA, Wang KK, Buttar NS et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology 2007; 132: 1226-33.
148. Wani S, Falk G, Hall M et al. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011; 9: 220-7.
149. Bulsiewicz WJ, Kim HP, Dellon ES et al. Safety and effi cacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic Barrett's esophagus. Clin Gastroenterol Hepatol 2013; 11: 636-42.
150. Hur C, Choi SE, Rubenstein JH et al. The cost eff ectiveness of radio frequency ablation for Barrett's esophagus. Gastroenterology 2012; 143: 567-75.
151. Anaparthy R, Gaddam S, Kanakadandi V et al. Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia. Clin Gastroenterol Hepatol 2013; 11: 1430-6.
152. Sikkema M, Looman CW, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106: 1231-8.
153. Pohl H, Wrobel K, Bojarski C et al. Risk factors in the development of esophageal adenocarcinoma. Am J Gastroenterol 2013; 108: 200-7.
154. Sepesi B, Watson TJ, Zhou D et al. Are endoscopic therapies appropriate for superfi cial submucosal esophageal adenocarcinoma? An analysis of esophagectomy specimens. J Am Coll Surg 2010; 210: 418-27.
155. Pech O, Bollschweiler E, Manner H et al. Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011; 254: 67-72.
156. Leers JM, DeMeester SR, Oezcelik A et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011; 253: 271-8.
157. Nentwich MF, von Loga K, Reeh M et al. Depth of submucosal tumor infi ltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. J Gastrointest Surg 2014; 18: 242-9.
158. Badreddine RJ, Prasad GA, Lewis JT et al. Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol 2009; 8: 248-53.
159. Bergeron EJ, Lin J, Chang AC et al. Endoscopic ultrasound is inadequate to determine which T1/T2 esophageal tumors are candidates for endoluminal therapies. J Th orac Cardiovasc Surg 2014; 147: 765-71.
160. Bulsiewicz WJ, Dellon ES, Rogers AJ et al. The impact of endoscopic ultra sound fi ndings on clinical decision making in Barrett's esophagus with high-grade dysplasia or early esophageal adenocarcinoma. Dis Esophagus 2014; 27: 409-17.
161. Pouw RE, Heldoorn N, Alvarez Herrero L et al. Do we still need EUS in the workup of patients with early esophageal neoplasia? A retrospective analysis of 131 cases. Gastrointest Endosc 2011; 73: 662-8.
162. Th osani N, Singh H, Kapadia A et al. Diagnostic accuracy of EUS in diff erentiating mucosal vs. submucosal invasion of superfi cial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc 2012; 75: 242-53.
163. Orman ES, Kim HP, Bulsiewicz WJ et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108: 187-95.
164. Gupta M, Iyer PG, Lutzke L et al. Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology 2013; 145: 79-86.
165. Shaheen NJ, Overholt BF, Sampliner RE et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011; 141: 460-8.
166. Overholt BF, Lightdale CJ, Wang KK et al. Photodynamic therapy with porfi mer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005; 62: 488-98.
167. Shaheen NJ, Greenwald BD, Peery AF et al. Safety and effi cacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71: 680-5.
168. Gosain S, Mercer K, Twaddell WS et al. Liquid nitrogen spray cryotherapy in Barrett's esophagus with high-grade dysplasia: long-term results. Gastrointest Endosc 2013; 78: 260-5.
169. Parrilla P, Martinez de Haro LF, Ortiz A et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003; 237: 291-8.
170. Corey KE, Schmitz SM, Shaheen NJ. Does a surgical antirefl ux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis. Am J Gastroenterol 2003; 98: 2390-4.
171. Oberg S, Wenner J, Johansson J et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005; 242: 49-54.
172. Chang EY, Morris CD, Seltman AK et al. The eff ect of antirefl ux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. Ann Surg 2007; 246: 11-21.
173. Anders M, Bahr C, El-Masry MA et al. Long-term recurrence of neoplasia and Barrett's epithelium after complete endoscopic resection. Gut 2014; 63: 1535-43.
174. Pasricha S, Bulsiewicz WJ, Hathorn KE et al. Durability and predictors of successful radiofrequency ablation for Barrett's esophagus. Clin Gastroenterol Hepatol 2014; 12: 1840-7.
175. Titi M, Overhiser A, Ulusarac O et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus. Gastroenterology 2012; 143: 564-6.
176. Phoa KN, Pouw RE, van Vilsteren FG et al. Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013; 145: 96-104.
177. Gaddam S, Singh M, Balasubramanian G et al. Persistence of nondysplastic Barrett's esophagus identifi es patients at lower risk for esophageal adenocarcinoma: results from a large multicenter cohort. Gastroenterology 2013; 145: 548-53.
178. Guarner-Argente C, Buoncristiano T, Furth EE et al. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc 2013; 77: 190-9.
179. Badreddine RJ, Prasad GA, Wang KK et al. Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc 2010; 71: 697-703.
180. Haidry RJ, Dunn JM, Butt MA et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK national halo RFA registry. Gastroenterology 2013; 145: 87-95.
181. Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol 2011; 106: 1899-908.
182. Zhou C, Tsai TH, Lee HC et al. Characterization of buried glands before and after radiofrequency ablation by using 3-dimensional optical coherence tomography (with videos). Gastrointest Endosc 2012; 76: 32-40.
183. Gupta N, Mathur SC, Dumot JA et al. Adequacy of esophageal squamous mucosa specimens obtained during endoscopy: are standard biopsies suffi cient for postablation surveillance in Barrett's esophagus? Gastrointest Endosc 2012; 75: 11-18.
184. Shaheen NJ, Peery AF, Overholt BF et al. Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc 2010; 72: 490-6.
185. Orlando RC. How good is the neosquamous epithelium? Dig Dis 2014; 32: 164-70.
186. Pouw RE, Gondrie JJ, Rygiel AM et al. Properties of the neosquamous epithelium after radiofrequency ablation of Barrett's esophagus containing neoplasia. Am J Gastroenterol 2009; 104: 1366-73.
187. Lee JK, Cameron RG, Binmoeller KF et al. Recurrence of subsquamous dysplasia and carcinoma after successful endoscopic and radiofrequency ablation therapy for dysplastic Barrett's esophagus. Endoscopy 2013; 45: 571-4.
188. Yasuda K, Choi SE, Nishioka NS et al. Incidence and predictors of adenocarcinoma following endoscopic ablation of Barrett's esophagus. Dig Dis Sci 2014; 59: 1560-6.
189. Kahaleh M, Van Laethem JL, Nagy N et al. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression. Endoscopy 2002; 34: 950-5.
190. Ferraris R, Fracchia M, Foti M et al. Barrett's oesophagus: long-term followup after complete ablation with argon plasma coagulation and the factors that determine its recurrence. Aliment Pharmacol Th er 2007; 25: 835-40.
191. Pouw RE, Bergman JJGHM. Radiofrequency ablation for Barrett's esophagus, for whom and by whom? Clin Gastroenterol Hepatol 2013; 11: 1256-8.
192. Moss A, Bourke MJ, Hourigan LF et al. Endoscopic resection for Barrett's high-grade dysplasia and early esophageal adenocarcinoma: an essential staging procedure with long-term therapeutic benefi t. Am J Gastroenterol 2010; 105: 1276-83.
193. Zemlyak AY, Pacicco T, Mahmud EM et al. Radiofrequency ablation off ers a reliable surgical modality for the treatment of Barrett's esophagus with a minimal learning curve. Am Surg 2012; 78: 774-8.
194. Fudman DI, Lightdale CJ, Poneros JM et al. Positive correlation between endoscopist radiofrequency ablation volume and response rates in Barrett's esophagus. Gastrointest Endosc 2014; 80: 71-7.
195. van Vilsteren FG, Pouw RE, Herrero LA et al. Learning to perform endoscopic resection of esophageal neoplasia is associated with signifi cant complications even within a structured training program. Endoscopy 2012; 44: 4-12.
196. Cook MB, Shaheen NJ, Anderson LA et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 2012; 142: 744-53.
197. Andrici J, Tio M, Cox MR et al. Hiatal hernia and the risk of Barrett's esophagus. J Gastroenterol Hepatol 2013; 28: 415-31.
198. Sikkema M, Looman CW, Steyerberg EW et al. Predictors for neoplastic progression in patients with Barrett's esophagus: a prospective cohort study. Am J Gastroenterol 2011; 106: 1231-8.